Valneva Plans Investor Presentations on Lyme Vaccine and Pipeline
Valneva will meet with institutional investors at several healthcare conferences in the U.S. and Europe. Management plans to discuss the regulatory outlook for its Lyme disease vaccine candidate, developed with Pfizer, with decisions expected in the next year. The company will also provide updates on its R&D pipeline.
Valneva’s leadership will join four investor events across Europe and the U.S. between mid-October and mid-November 2026. These include a Paris biotech seminar and healthcare conferences in Boston, New York, and London, featuring moderated discussions and meetings with institutional investors.
The company plans to spotlight its Lyme disease vaccine candidate, being developed with Pfizer, as a near-term regulatory catalyst. It will also review pipeline progress, including its Shigella program, and outline possible value creation if the Lyme vaccine wins approval and is commercialized.
If regulators clear the Pfizer-partnered Lyme vaccine, it could add a new prevention option for people in tick-exposed regions, potentially reducing disease burden. Valneva’s pipeline updates may also affect investor confidence, shaping resources for future vaccines. For now, the main near-term impact is informational: patients, clinicians, and investors may watch regulatory decisions and pipeline progress, but availability and uptake would depend on approvals, recommendations, and manufacturing.